Clinical trials
Prostate clinical trials
Below are recruiting prostate clinical trials, each written for real people, not researchers. We’re tracking 1,365 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07567846RecruitingPhase 1/Phase 2
GDC-1261 Safety and Activity in Advanced Prostate Cancer
This early-stage trial tests a new drug called GDC-1261 in men with advanced prostate cancer that has spread or gotten worse despite previous treatment. The study will look at whether the drug is safe and whether it helps slow or shrink the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT07455903RecruitingPhase 2
Hormone therapy before surgery for high-risk prostate cancer
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
Miami, FloridaAges 18 years+ - NCT06654336RecruitingPhase 2
Targeted therapy with or without hormone therapy for prostate cancer that has spread a little
This trial tests whether targeting the spots where cancer has returned with radiation or surgery, with or without hormone therapy, can help control prostate cancer that has come back in a few places after previous treatment.
Hamilton, OntarioAges 18 years+ - NCT06850545Recruiting
Lu-177 treatment for PSMA-positive metastatic prostate cancer
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Kuopio, Northern SavoniaAges 18 years+ - NCT06461793RecruitingPhase 2
Higher dose radiation with hormone therapy for high-risk prostate cancer
This trial tests a higher dose of radiation given in fewer sessions (hypofractionated) combined with hormone therapy for men with high-risk prostate cancer that has not spread. A gel spacer called SpaceOAR is used to protect the rectum. The goal is to see if this approach is safe and effective.
SeoulAges 20 years+ - NCT06320067RecruitingPhase 3
Testing treatments for metastatic hormone-sensitive prostate cancer
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
BarnsleyAges 18 years+ - NCT06184464Recruiting
Shrinking the prostate before radiation for prostate cancer
This trial tests how well the hormone drug leuprorelin acetate shrinks the prostate before radiation therapy for men with prostate cancer. The goal is to make radiation safer and more effective.
Terrassa, BarcelonaAges 18–95 - NCT05998278Recruiting
Personalized prostate biopsy study
This trial is testing a more personalized way to perform prostate biopsies. It's for men who have a suspicious finding on exam or imaging, or a higher PSA level, and who have had a special MRI that suggests cancer. The goal is to improve accuracy and reduce unnecessary biopsies.
Fuzhou, FujianAges 50–95 - NCT05665738Recruiting
Two-visit HDR radiation to treat early prostate cancer
This study tests a radiation treatment delivered in two fractions (two sessions) as the only treatment for certain early-stage prostate cancers. It may help you avoid other treatments, like hormone therapy, depending on whether your cancer and health history fit the study.
San Francisco, CaliforniaAges 18 years+ - NCT05457699RecruitingPhase 2
Targeted radiation to control prostate cancer spread
This Phase 2 study tests whether a focused form of radiation given after your cancer responds to medicine can help keep metastatic prostate cancer under control. It may help by “consolidating” your current good response, potentially delaying progression.
Montreal, QuebecAges Any age - NCT05570994Enrolling by invitationPhase 1/Phase 2
PSMA-targeted radioactive drug for advanced prostate cancer
This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.
Vancouver, British ColumbiaAges 18 years+ - NCT05608694Recruiting
MRI screening for men at high risk of prostate cancer
This trial is testing whether MRI scans can help screen for signs of prostate cancer in men who have not been diagnosed yet but are at higher risk. It may help find concerning changes earlier so doctors can follow up sooner.
Chicago, IllinoisAges 18 years+ - NCT05406999RecruitingPhase 2
Intense hormone treatment before prostate surgery for high-risk cancer
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
Nanjing, JiangsuAges 18–80 - NCT03903835RecruitingPhase 3
Biomarker-guided treatment for metastatic prostate cancer
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
AalstAges 18 years+ - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Duarte, CaliforniaAges 18 years+ - NCT06420115Recruiting
Comparing needle sizes for prostate MRI-targeted biopsy
This study compares two different needle sizes used during a prostate biopsy to see which one finds cancer more accurately and causes fewer side effects. It is for people who have not been diagnosed with prostate cancer before and have a suspicious MRI finding.
Padua, ItalyAges 18 years+ - NCT06369610RecruitingPhase 2
Less hormone therapy with radiation for prostate cancer
This trial tests whether some men with high-risk prostate cancer can safely receive less hormone therapy when combined with radiation. It aims to reduce side effects while still effectively treating the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05818683RecruitingPhase 1
Pasritamig plus other drugs for advanced prostate cancer
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
Sarasota, FloridaAges 18 years+ - NCT06702995RecruitingPhase 1/Phase 2
Study of XNW5004 plus enzalutamide for advanced prostate cancer
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT04175431RecruitingPhase 2
PSMA or FACBC PET scan guided treatment for prostate cancer recurrence
This Phase 2 study tests using a special PET/CT scan (PSMA or FACBC) to guide treatment for prostate cancer that has come back after surgery and radiation. The goal is to see whether this scan-based approach can better target cancer in the prostate area (and help plan the right treatment).
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06387056RecruitingPhase 2
Gene-guided hormone therapy before prostate cancer surgery
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Xiamen, FujianAges 18 years+ - NCT07150715RecruitingPhase 2
Radioactive drug plus precise radiation for recurrent prostate cancer
This trial tests a powerful radioactive drug (either alpha or beta) combined with precise radiation to treat prostate cancer that has come back in a few spots outside the prostate. It may help men whose cancer is still hormone-sensitive and has not spread widely.
Los Angeles, CaliforniaAges 18 years+ - NCT04704505RecruitingPhase 2
Testosterone-like treatment plus radium for bone-spread prostate cancer
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Baltimore, MarylandAges 18 years+ - NCT05656794RecruitingPhase 2
Radiation after treatment for prostate cancer that has spread
This trial studies whether adding a targeted course of radiation to the prostate area after initial systemic treatment can improve outcomes for people with metastatic prostate cancer. It may help control the cancer by treating remaining disease after medicines have started working.
Toronto, OntarioAges 18–100
Hear when a new Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate?
- Yes. Clin2 currently lists 1,365 recruiting prostate studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.